(perampanel) - Partial-onset seizures Halaven (eribulin) - Metastatic breast cancer Iomeron (iomeprol) - Non-ionic contrast medium Methylcobal (methylcobalamin) - Peripheral neuropathy Myonal (eperisone) - Muscle relaxant Selbex (teprenone) - Gastric ulcers and gastritis Zonegran (zonisamide) - Partial-onset seizures Gliadel Wafer (carmustine) - Treatment for Brain Tumors Lenvima (lenvatinib) - Thyroid Cancer or Kidney Cancer Aricept Aricept accounted for 40% of Eisai's revenue as of March 2010. The main competitor to Aricept is a generic formulation from Ranbaxy Labs. Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product. See also Biotech and pharmaceutical companies in the New York metropolitan area References External links Wiki collection of bibliographic works on Eisai Life sciences industry Pharmaceutical companies based in Tokyo Companies listed on the Tokyo Stock Exchange Pharmaceutical companies established in 1941 Japanese companies established in 1941 Japanese brands Pharmaceutical companies based in New Jersey